KLF12 overcomes anti-PD-1 resistance by reducing galectin-1 in cancer cells

Area of Science:

• Immunology
• Cancer Biology
• Molecular Biology

Background:

• Immune checkpoint blockade has transformed cancer therapy but faces challenges due to treatment resistance in many patients.
• The role of Krüppel-like factor 12 (KLF12), a transcriptional inhibitor, in tumor immunity remains largely unexplored.
• Understanding factors that limit immunotherapy efficacy is crucial for improving patient outcomes.

Purpose of the Study:

• To investigate the role of KLF12 in regulating anti-tumor immunity and its association with immunotherapy resistance.
• To elucidate the molecular mechanisms by which KLF12 affects CD8+ T cell infiltration and function within the tumor microenvironment.
• To identify potential therapeutic targets for overcoming immunotherapy resistance.

Main Methods:

• Flow cytometry was used to assess the relationship between KLF12 and CD8+ T cells.
• Molecular techniques including qPCR, Western blot, ChIP-PCR, and luciferase assays were employed to study KLF12's regulatory mechanisms.
• In vivo studies utilized mouse tumor models, testing combination therapies involving anti-PD-1 and KLF12 or Galectin-1 inhibitors.

Main Results:

• Tumor KLF12 expression was found to correlate with resistance to cancer immunotherapy.
• KLF12 was demonstrated to suppress both the infiltration and function of CD8+ T cells in vitro and in vivo.
• KLF12 inhibits Galectin-1 (Gal-1) expression by binding to its promoter, thereby enhancing CD8+ T cell activity.

Conclusions:

• KLF12 negatively regulates CD8+ T cell infiltration and function, contributing to immunotherapy resistance.
• The KLF12/Gal-1 signaling axis represents a novel pathway influencing anti-tumor immunity.
• Targeting the KLF12/Gal-1 axis offers a potential therapeutic strategy for patients resistant to current immunotherapies.